Compare Charles River Laboratories Intl. Inc (CRL) vs Danaos Corporation (DAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Danaos Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $286.25 (market cap $13.46B), while Danaos Corporation trades at $137.74 (market cap $2.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.5× Danaos Corporation's market cap, and Danaos Corporation pays a 2.67% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | DAC | |
|---|---|---|
Market Cap | $13.46B | $2.46B |
Sector | Health | Technology |
52-Week High | $282.00 | $143.15 |
52-Week Low | $145.57 | $84.05 |
Enterprise Value | $16.30B | $2.44B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Danaos Corporation (DAC) trades at $137.35, down 0.7% on the day, but maintains strong technical and fundamental momentum. The stock shows a bullish technical signal with key support at $133 and resistance at $138. Fundamentally, DAC demonstrates exceptional profitability with a 51.26% net income margin and attractive valuation metrics including a P/E of 4.57 and P/B of 0.61. Recent Q2 2026 earnings beat expectations with EPS of $7.29 versus $6.80 expected, continuing a pattern of strong quarterly performance.
DAC presents a compelling value opportunity with deep discount to book value and consistent earnings outperformance. The company's record $4.6 billion contracted revenue backlog provides visibility, while quarterly dividends of $0.90 per share enhance shareholder returns. Primary risks include shipping industry cyclicality and capital expenditure requirements for fleet expansion. Analyst sentiment is evenly split between Buy and Hold ratings, reflecting the stock's value proposition balanced against sector dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →
